GSK and its parnet Impax Pharmaceuticals reported positive results with its drug IPX066 in a phase III trial with Parkinson's disease patients. The extended-release version of the drug induced a 37% drop in off-time (when a medication's affect has worn off) compared to a 17% decrease in patients taking an immediate release version of the drug.
Under the terms of the companies' development and commercialization agreement, Impax wil complete the current phase III program for IPX066 and will file the drug in the US later in 2011. GSK has an exclusive license to commercialize the drug worldwide, except in the US and Taiwan. Impax shares jumped more than 10% on the clinical results news.
Posted by Bruce Lehr March 16th 2011.